626 results about "Left Ventricles" patented technology

Apparatus and methods are described including placing, into a subject's body, a blood-pump tube, with an impeller disposed within the blood-pump tube. At least one blood-pressure-measurement element extends to at least an outer surface of the blood-pump tube, such that the distal end of the blood-pressure-measurement element is in direct fluid communication with a bloodstream of the subject outside the blood-pump tube at a location that is proximal to blood-inlet opening(s) defined by the blood-pump tube. Blood is pumped through the blood-pump tube, using the impeller. Pressure of the bloodstream of the subject outside the blood-pump tube is measured by measuring blood pressure at the distal end of the left-ventricular blood-pressure-measurement element. Other applications are also described.

Various systems, devices, and methods are disclosed herein for treating acute myocardial infarction (AMI) patients using a heart pump controlled in a manner that maximizes mechanical unloading of the left ventricle in the presence of cardiovascular instability and minimizes myocardial oxygen consumption (MVO2) and consequentially infarct size to prevent the development of subsequent heart failure. In a closed feedback system, the system can include a sensor configured to generate an output used to measure or calculate a left ventricular systolic pressure (LSVP) within the left ventricle of a heart and a controller coupled to a heart pump. The controller can be configured to measure or calculate the LVSP based on the output of the sensor and to control an operation of the heart pump to maximize mechanical unloading of the left ventricle based on the measured or calculated LVSP.

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and / or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

A device comprises an implantable blood pump receivable in a sheath for percutaneous delivery. The implantable blood pump comprises a collapsible impeller mounted in a collapsible impeller cage, and a drive device mounted in a housing. The housing is in connection between a first end of a catheter and the collapsible impeller cage. The drive device is adapted for rotating the collapsible impeller. A retractable support structure is adapted to extend from the catheter. The extended retractable support structure is adapted to engage with the wall of the aorta for allowing the implantable blood pump to be secured in the left ventricle. The collapsible impeller cage comprises an inlet and an outlet. The inlet is adapted to receive blood from the left ventricle. The outlet directs blood in the direction of the atrioventricular valve.

Apparatus and methods are described including delivering a left-ventricular assist device to a subject's aorta. The device including a distal-tip element that defines a straight proximal portion, and a curved distal portion, the curved distal portion defining first and second curves with an elongated straight portion between the first and second curves. The distal-tip element is centered with respect to the aortic valve using the curved distal portion of the distal-tip element, to thereby guide the device through the subject's aortic valve atraumatically. A pump pumps blood through from the subject's left ventricle to the subject's aorta. Other applications are also described.

Apparatus and methods are described including delivering a left-ventricular assist device to a subject's left ventricle. A tube is positioned such that a proximal portion of the tube traverses an aortic valve of the subject, and a distal portion of the tube is disposed within a left ventricle of the subject. A pump pumps blood through the tube from the subject's left ventricle to the subject's aorta such as to cause the proximal portion of the tube to be maintained in an open state, and to cause at least a portion of the tube to become curved. Other applications are also described.

Apparatus and methods are described including a ventricular assist device that includes an impeller configured to be placed inside a left ventricle of a subject. A driving magnet is coupled to a motor and is rotated by the motor. A driven magnet is magnetically coupled to the driving magnet and is rotated by the driving magnet. A drive cable extends from the driven magnet and imparts rotational motion from the driven magnet to the impeller. A set of sensors is configured to detect a magnetic phase difference between the driven magnet and the driving magnet. A computer processor receives the detected magnetic phase difference and determines a physiological parameter of the subject, at least partially in response thereto. Other applications are also described.

The disclosure relates to heart have prostheses with the reduced need of pacemaker implantation and improved means for positioning the replacement heart valve. In one aspect of the present disclosure, the stent scaffold of the valve prosthesis includes axially extending locators. The locators may be positioned within the cusp of the native aortic valve. Placement of the locators within the cusps may prevent further proximal movement of the stent scaffold into the left ventricle. By adjusting the location of the proximal end of the locators with respect to the proximal end of the stent scaffold, infra-annular placement of the stent scaffold in the aortic annulus may be assured. In another aspect, means for visualizing the positioning of replacement heart valves at an implant site inside an individual's body is disclosed.

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and / or left ventricular pressure.

The invention relates to a hypertrophic obstructive cardiomyopathy virtual resection operation curative effect evaluation method based on individualized computational fluid mechanics, which can give visual postoperative hemodynamic indexes, predict postoperative curative effects, find an optimal resection scheme and realize preoperative accurate intelligent evaluation. Comprising the following steps of: acquiring coronary artery enhanced computed tomography image data, acquiring a coronary artery enhanced computed tomography image of a patient, and outputting and storing the coronary artery enhanced computed tomography image in a DICOM (Digital Imaging and Communications in Medicine) format; preprocessing image data, and segmenting and reconstructing a left ventricle-outflow tract structure three-dimensional model; setting a virtual excision scheme at the fleshy part; constructing a surgical resection model, and importing the model into finite element analysis software for solving; and the virtual postoperative curative effect is visualized. Verification and curative effect prediction of a patient excision scheme can be realized, and the operation success rate of a hypertrophic obstructive cardiomyopathy patient is improved.

The invention provides an echocardiogram video abstraction method based on a hierarchical space-time attention mechanism, and the method comprises the steps: obtaining an echocardiogram, inputting the echocardiogram into an anatomy and physiological basic model of a key frame recognition task, and obtaining key frame information; inputting the key frame information into a multi-dimensional spatial-temporal feature extraction model to obtain feature information and frequency domain information; fusing the feature information and the frequency domain information; performing key frame enhancement processing on the fusion information by adopting an SE channel attention mechanism to obtain key frame anatomical feature expression; processing the key frame anatomical feature expression by adopting a key frame backtracking strategy and a classification network to obtain a key frame identification classification result; performing left ventricle segmentation on the classified image by adopting an improved U-Net left ventricle region segmentation network; estimating the area and volume of the left ventricle based on a segmentation result; fusing the estimated left ventricular area and volume by adopting a hierarchical attention mechanism and a cross-layer information fusion strategy to obtain a ventricular volume result; according to the method, through abstract extraction of the key information of the ultrasonic cardiac video, the clinical practicability of intelligent screening and auxiliary diagnosis of cardiovascular diseases based on ultrasonic is improved.

An aorta intervention catheter device for heart failure comprises a catheter and a bag body arranged at one end of the catheter, an elastic diaphragm is arranged in the bag body, an inner cavity of the bag body is divided into a blood chamber and an air chamber by the elastic diaphragm, the blood chamber is communicated with the catheter, an exhaust assembly is arranged on the bag body, and the air chamber is connected with an air source connector arranged on the bag body; the other end of the catheter is a proximal end, first guide films which are staggered at intervals and inclined towards one side of the proximal end and second guide films which are inclined towards a distal end are arranged on the inner wall of the catheter, and first guide holes and second guide holes which correspond to the first guide films and the second guide films and are communicated with an inner cavity of the catheter are respectively formed in the outer wall of the catheter; the proximal side of the second guide film is provided with at least one set of third guide films which are fixed to the inner wall of the catheter, incline towards the distal end and are tightly attached to each other to be closed. The aorta is directly intervened to enter the heart, and coronary artery blood perfusion is increased in the diastolic period; the left ventricular post-load is reduced in the systolic period, and the heart failure can be more directly treated.

The invention provides a left heart data analysis method and system based on image segmentation, and relates to the technical field of medical image processing. Comprising the following steps: acquiring cardiac ultrasound image data and preprocessing; performing image segmentation on the preprocessed image data to obtain a segmentation result including a left ventricle, a left ventricular wall and a left atrium; searching a boundary line of the left ventricle and the left atrium, selecting two boundary points corresponding to the minimum and maximum abscissas in the boundary line as left and right mitral valve ring points respectively, and establishing a long axis based on the mitral valve ring midpoint and the cardiac apex point; modeling the ventricle into a structure formed by superposing a plurality of discs along the long axis direction, and obtaining the diameter of the corresponding disc; based on the obtained diameters of the corresponding discs, the left ventricular volumes in the diastolic period and the systolic period are calculated respectively, and the left ventricular ejection fraction is calculated. According to the method, image segmentation and geometric modeling are fused to achieve accurate calculation of the cardiac ejection fraction, meanwhile, the accuracy of cardiac structure image segmentation is improved, and an interpretable ejection fraction estimation process is achieved.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

Systems and methods for delivering a device for regulating blood pressure across a patient's atrial septum are provided. The delivery apparatus may include a first catheter, a hub having one or more engagers disposed thereon, the one or more engagers configured to releasably engage with a first expandable end of the shunt in a contracted delivery state within a lumen of a sheath, and an second catheter extending through a center lumen of the first catheter and the hub, wherein the first catheter, the hub, and the second catheter are independently moveable relative to the sheath. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices also may be used to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The invention discloses a double-balloon type left ventricle auxiliary device which comprises an inlet tube, an outer balloon, an elastic support, an inner balloon, a catheter and a connecting piece. The inlet pipe is provided with a plurality of inflow windows and a one-way valve for controlling one-way flow of blood; the outer balloon has a folded state and an expanded state, in the conveying process, the outer balloon is in the folded state and can be contained in the conveying sleeve, and when the outer balloon reaches a designated position, the outer balloon is in the expanded state; the elastic support is attached to the surface of the external balloon, the elastic deformation of the elastic support enables the external balloon to be switched between a folded state and an expanded state, and the elastic support can provide radial supporting force in the expanded state, so that the external balloon is expanded and keeps a fixed volume; the internal balloon is arranged inside the external balloon, and contraction and expansion are realized by injecting gas or liquid, so that the volumes of inner cavities of the internal balloon and the external balloon are periodically changed, and the internal balloon and the external balloon are used for sucking and discharging blood; the catheter is provided with a medium cavity and a guide wire cavity, and the medium cavity is communicated with the internal balloon.

A method of delivering a pacing lead may include locating a potential implantation site adjacent to or within the triangle of Koch region of a patient's heart. The method may include advancing a pacing lead to the potential implantation site. The pacing lead has an elongate body and a fixation element coupled to a distal portion and attachable to the right-atrial endocardium adjacent to or within the triangle of Koch region. The method may include implanting the pacing lead at the potential implantation site to or sense electrical activity of the left ventricle in the basal and / or septal region of the left ventricular myocardium of the patient's heart. The pacing lead may include a lumen configured to receive a guide wire. A sheath of a delivery system used to deliver the pacing lead may include two or more curves to facilitate implanting the pacing lead at the implantation site.

A method, for use at a mitral valve of a heart of a subject, is provided which includes advancing a transluminal sheath into a femoral vein of the subject, through an inferior vena cava of the subject, into a right atrium of the subject, and transseptally into a left atrium of the subject. A surrounding-sheath is advanced out of a distal end of the transluminal sheath, into the left atrium, and toward a commissure of the mitral valve. An anchor is implanted by advancing the anchor out of the surrounding-sheath into a left ventricle of the subject, such that the anchor helically wraps around left ventricular mitral valve tissue. The surrounding-sheath is then extracted from the heart and then, a guide wire is advanced through the transluminal sheath. Other embodiments are also described.

The systems, devices, and methods presented herein use a heart pump to obtain measurements of cardiovascular function. The heart pumps described herein can operate in parallel with and unload the heart. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as pressure or motor current, then calculate and display one or more metrics of cardiovascular function. These metrics, such as left ventricular end diastolic pressure (LVEDP), left ventricular pressure, and contractility, provide valuable information to a user regarding a patient's state of heart function and recovery.

A method is provided that includes inserting an inflow cannula of a left ventricular assist device (LVAD) of a LVAD system into a left chamber of a heart of a patient transeptally via a right atrium and a superior vena cava (SVC). An outflow cannula of the LVAD is coupled to a left subclavian artery or a left axillary artery. Other embodiments are also described.

The illustrative methods and systems facilitate one or more dynamic analyses that can characterize and identify synchronization between acquired cardiac signals and photoplethysmography signals to predict / estimate the presence, location, and / or severity of abnormal cardiovascular conditions or diseases, including, for example, but not limited to, coronary artery disease, heart failure (including but not limited to indicators of disease or condition, such as abnormal left ventricular end-diastolic pressure disease), and pulmonary hypertension. In some embodiments, statistical properties of the synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical properties of a histogram of synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical and / or geometric properties of a Poincare map of synchronization between the cardiac signal and the photoplethysmography signal are evaluated.

An injectable hydrogel for heart failure treatment with myocardial tissue repair function and its preparation method and use are disclosed. The hydrogel is prepared by chelating alginic acid and multivalent cations. The hydrogel is loaded with an active substance for repairing cardiac injury. The active substance is recombinant humanized collagen type III. The hydrogel is administrated into the left ventricle free wall by transendocardial injection. Implanting the hydrogel in the myocardium can increase the thickness of the left ventricular wall, adjust the stress of the ventricular wall, affect the morphology of the left ventricle, and prevent or reverse left ventricular enlargement. Further, the hydrogel is loaded with a new recombinant humanized collagen material that has the function of repairing cardiac tissue injury to further improve cardiac function and promote cardiac repair.

Methods and systems are provided for identifying cardiac cycles for evaluating left ventricle function using only image data. In one example, a method includes obtaining a sequence of medical image frames of a heart of a patient over a plurality of cardiac cycles, wherein each medical image frame depicts the same apical view of the heart, using a timing model to generate an output that is useable to label each frame of the sequence by cardiac cycle subphase and using the output to determine the suitability of each cardiac cycle for performing an automated measurement. The method may further include using the suitability of each cycle to determine if an automated measurement should be performed on each cycle, where automated measurements are performed on medical image frames corresponding to suitable cycles and automated measurements are not performed on medical image frames corresponding to unsuitable cycles.

A non-invasive diagnostic system assesses the optimal timing for aortic valve replacement (AVR) by quantifying left-ventricular Frank-Starling reserve before irreversible myocardial damage occurs. The system (i) acquires left-ventricular ejection time (LVET) and other systolic-time intervals from optical or vibrational sensors positioned on the patient, (ii) induces a reversible preload change—e.g., passive leg raise or posture transition—to create a controlled venous-return increment, (iii) processes the paired baseline and post-maneuver waveforms to extract systolic time interval metrics, and (iv) analyzes the ΔLVET / Δpreload relationship against historical or population references. A diminished LVET response signals loss of contractile reserve, enabling timely AVR while myocardial changes remain reversible. The platform integrates measurement hardware, a data-processing engine, a data-analysis module, and a reporting interface, and may be configured as a wrist, ring, chest, or ear sensor. The method can be implemented at point-of-care without operator-dependent imaging or invasive monitoring.

The embodiment of the invention provides a monitoring system and device of a ventricular assist device, and relates to the technical field of medical instruments.The system comprises the ventricular assist device and a monitoring device.The monitoring device executes the following monitoring method that a rotating speed signal of the current rotating speed of the ventricular assist device is obtained, and determine a first pressure signal of the left ventricular pressure of the patient's heart; based on the rotating speed signal and the first pressure signal, a target correlation value representing the correlation degree between the current rotating speed and the left ventricular pressure is calculated; and determining a target support state of the ventricular assist device based on a deviation between the target correlation value and a preset reference value. By applying the scheme provided by the embodiment, the support state of the ventricular assist device can be continuously and accurately monitored in real time.

The disclosure deals with methodology and corresponding apparatus / system subject matter for image-based estimation of left ventricular myocardial stiffness. Increased left ventricular myocardial stiffness is a key factor in the development and progression of heart failure. Despite the potential impact on the clinical management of heart failure, there is currently a lack of available techniques to assess left ventricular myocardial stiffness. To address this limitation, a simple protocol is disclosed for processing routine echocardiographic imaging data to estimate left ventricular myocardial stiffness, with protocol specification for patients at risk for heart failure with preserved ejection fraction, for both sensitivity and translational feasibility of the obtained estimates of left ventricular myocardial stiffness.

The invention discloses a hypertrophic cardiomyopathy (HCM) preoperative planning and operation effect evaluation method based on accurate digital labeling. The method comprises the following steps: performing digital labeling on the thickness of each wall of a left ventricle of a preoperative heart 3D digital model; according to the digital labeling result of the preoperative heart 3D digital model and the normal value of the thickness of the left ventricular wall, a doctor manually depicts the predicted resection range and confirms the predicted retention thickness; measuring the predicted resection volume, the predicted resection area and the left ventricular end diastolic volume after the predicted resection volume is resected; digitally marking the thickness of each wall of the left ventricle of the postoperative heart 3D digital model, and measuring the volume of the corresponding left ventricle in the end diastole; and taking the predicted resection range, the predicted retention thickness, the predicted resection volume, the predicted resection area and the predicted volume as first evaluation data, taking corresponding parameters of the postoperative heart 3D digital model as second evaluation data, and generating an operation evaluation result according to the conformity of the first evaluation data and the second evaluation data.

The invention discloses a pyrimidinedione derivative as well as a preparation method and application thereof. Molecules of the pyrimidinedione derivative have better myosin inhibitory activity, also have antioxidant effects of DPPH and / or MDA and the like and anti-ferroptosis activity, and can be applied to treatment / prevention of heart myosin, anti-oxidative stress and anti-ferroptosis mechanism related diseases. The diseases or symptoms mainly comprise hypertrophic cardiomyopathy, diastolic heart failure, left ventricular hypertrophy, heart diseases with pathophysiological characteristics related to the hypertrophic cardiomyopathy, or other disease states and conditions which are obvious to those skilled in the art, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof, and a pharmaceutical composition containing the same.

Methods and devices for transvascular prosthetic chordae tendinea implantation are disclosed. A catheter is advanced into the left atrium, through the mitral valve, and into the left ventricle. A ventricular anchor is deployed from the catheter and into a wall of the left ventricle, leaving a ventricular suture attached to the ventricular anchor and extending proximally through the catheter. A leaflet anchor is deployed to secure a mitral valve leaflet to a leaflet suture, with the leaflet suture extending proximally through the catheter. The leaflet suture is secured to the ventricular suture to limit a range of travel of the leaflet in the direction of the left atrium. Also disclosed is an assembled in situ mitral valve leaflet restraint, having a neo papillary muscle and a neo chordae tendinea.

The invention provides a prediction method and device for diagnosing myocardial amyloidosis, and is applied to the technical field of data processing. The method comprises the steps of performing data cleaning processing on a first training sample set to generate a second training sample set; performing missing value supplement processing on the second training sample set to generate a target training sample set; processing a preset myocardial amyloidosis prediction model based on the target training sample set and the verification sample set to generate a target myocardial amyloidosis prediction model; processing the clinical parameter information of the target user to generate target physiological parameter information; processing the living habit information of the target user to generate a dynamic risk adjustment factor; the target physiological parameter information and the dynamic risk adjustment factor are processed based on the target myocardial amyloidosis prediction model, early warning information is generated, and the early warning information is used for representing the relevance between the target user and myocardial amyloidosis, hypertrophic cardiomyopathy and hypertension left ventricular hypertrophy.